Aegle Therapeutics

Aegle Therapeutics is a private, clinical-stage biotech founded in 2015 and based in Miami, Florida, operating in the biologics sector. The company is developing a novel therapeutic platform based on extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs), with its lead program AGLE-102 in a Phase 1/2 trial for Recessive Dystrophic Epidermolysis Bullosa (RDEB). Aegle's technology aims to leverage the inherent signaling and cargo-delivery functions of EVs to treat rare diseases with high unmet need, positioning it at the forefront of the emerging EV therapeutics field. The company is currently pre-revenue and focused on advancing its clinical pipeline.

Proprietary platform for harvesting and developing therapeutic extracellular vesicles (EVs), including exosomes, derived from mesenchymal stem cells (MSCs). The EVs deliver a natural payload of biomolecules (proteins, nucleic acids) to exert regenerative, immunomodulatory, and anti-inflammatory effects.

Aegle operates in the emerging and competitive field of extracellular vesicle/exosome therapeutics. It faces competition from other biotech startups (e.g., Codiak BioSciences, Evox Therapeutics) and academic institutions developing EV-based platforms. For RDEB specifically, competitors include gene therapy approaches, protein replacement strategies, and other cell-based therapies, though Aegle's cell-free EV approach is a distinct modality.